476 results on '"Reddy, Sunil"'
Search Results
2. Health risk assessment of nitrate and fluoride toxicity in groundwater contamination in the Nagarkurnool watershed region of Telangana state
3. Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.
4. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
5. ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study
6. Unbalanced autosomal translocation identification of unbalanced 1; 9 autosomal translocation in a gir (bos indicus) bull calf
7. Floating Drug Delivery Systems: A Review
8. Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.
9. Comparative Study of Oral Dexmedetomidine and Oral Midazolam on Postoperative Recovery Characteristics of Paediatric Patients after Sevoflurane Anaesthesia
10. Oncologic outcomes with and without amniotic membranes in robotic-assisted radical prostatectomy: A propensity score matched analysis
11. Impact of human placental derivative allografts on functional and oncological outcomes after radical prostatectomy: a literature review
12. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
13. Abstract 16450: Increased Monocyte Count and Neutrophil-to-Lymphocyte Ratio With ICI Myocarditis
14. Does type of robotic platform make a difference in the final cost of robotic-assisted radical prostatectomy?
15. Nerve spare robot assisted laparoscopic prostatectomy with amniotic membranes: medium term outcomes
16. Robotic-assisted radical prostatectomy in young adults: age-stratified oncological and functional outcomes
17. History of Robotic Surgery
18. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry
19. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
20. Outcomes of Salvage Robot-assisted Radical Prostatectomy After Focal Ablation for Prostate Cancer in Comparison to Primary Robot-assisted Radical Prostatectomy: A Matched Analysis
21. Patient surgical satisfaction after da Vinci® single-port and multi-port robotic-assisted radical prostatectomy: propensity score-matched analysis
22. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy
23. Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec
24. Evidence-based evolution of our robot-assisted laparoscopic prostatectomy (RALP) technique through 13,000 cases
25. Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the genetic/biologic mechanism of racial disparity: Update
26. Da Vinci SP platform updates and modifications: the first impression of new settings
27. Intracranial Tumor Control After Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma
28. Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-d-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy
29. Correction to: Does type of robotic platform make a difference in the final cost of robotic-assisted radical prostatectomy?
30. THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY
31. A Novel Intersection - Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient with Advanced Cutaneous Squamous Cell Carcinoma: a Case Report
32. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
33. 622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma
34. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy
35. Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk
36. Power comparison of CMOS and adiabatic full adder circuit
37. 1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial
38. Safety and Efficacy of Transvenous Lead Extraction Utilizing the Evolution Mechanical Lead Extraction System: A Single-Center Experience
39. PO-01-030 HIGH-FREQUENCY LOW-TIDAL VOLUME MECHANICAL VENTILATION IS ASSOCIATED WITH IMPROVED ACUTE AND LONG-TERM OUTCOMES IN PATIENTS UNDERGOING CATHETER ABLATION FOR ATRIAL FIBRILLATION ABLATION
40. A PROSPECTIVE STUDY OF DISTAL HYPOSPADIAS IN A TERTIARY CARE HOSPITAL.
41. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
42. A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma
43. Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
44. Supplemental Table 4 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
45. Supplemental Figure 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
46. Supplemental Table 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
47. Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
48. Supplemental Figure 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
49. Supplemental Table 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
50. Data from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.